Technologiepark Basel in 2020
The year 2020 was an eventful year for Technologiepark Basel and its tenants. At the beginning of the year, the Technologiepark Basel could integrate the space of the former “Basel Incubator.” With the addition of the directly adjacent lot of approximately 380m2, the total footprint of Technologiepark Basel increased to approximately 6,700m2. The additional real estate was already fully rented before its inclusion in the site. The outbreak of the Covid-19 pandemic impacted the operations of the Technologiepark Basel. Many events had to be postponed or moved online, and the home office replaced working on site. All parties involved showed a great deal of patience and resilience. Fortunately, there were no company withdrawals in 2020 due to the Covid-19 pandemic. Many tenants could secure additional financing and even achieve growth in many different areas. The total number of employees working at Technologiepark Basel, for instance, increased to over 240. Moreover, one company highlight deserves special mention here: NBE Therapeutics was successfully sold to Boehringer Ingelheim for CHF 1.3 billion in December 2020.
Rental Area: 6,700m2
Start-up Employees: >240
Occupancy Rate: 90%
«The Technologiepark Basel offers us ideal infrastructural conditions for further development and growth at Polyneuron. The Technologiepark Basel is home to a lively network of life sciences companies, all of which contribute to the creation of an exciting, industry-specific working environment.»
«The modern infrastructure and the services offered in the Technologiepark Basel provide us with an optimal framework for the growth and development of our company. In addition, the proximity to other start-ups enables important and valuable exchange and interactions. The Technologiepark is thus the ideal environment for further development of any start-up.»
«The infrastructure and services of the Technologiepark Basel yield synergies which enable our young company to grow sustainably. Thanks to the integrated laboratory facilities, we are able to efficiently advance research and fundraising under one roof. We have also always been able to count on the expertise and active support of the Technologiepark team for user-specific extensions and conversions.»
For further information please contact email@example.com
Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen A...
Cellestia Biotech receives Orphan Drug Designation from the ...
Anaveon to raise CHF 110 million in oversubscribed Series B ...
Kinarus receives 7 Million CHF Grant from the Swiss Federal ...